Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales

A. J. Sutton*, N. J. Gay, William Edmunds

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

A vaccination programme offering hepatitis B (HBV) vaccine at reception into prison has been introduced into selected prisons in England and Wales. The work here considers the impact of prison vaccination on the incidence and prevalence of hepatitis B virus (HBV) in the injecting drug user (IDU) population of England and Wales. A dynamic model of the transmission of HBV in IDUs is developed with key model assumptions and parameters being subject to sensitivity analyses. The base case model (that assumes that the vaccination coverage on prison reception is 5% in 2002, 10% in 2003 and then increases linearly up to 50% of prison receptions being vaccinated by 2006) predicts that the incidence of HBV in IDUs might be reduced by almost 80% in 12 years, and the HBV prevalence (IDUs ever infected by HBV) may be reduced from approximately 18% in 2002 to 7% in 2015. The model presented here demonstrates that HBV vaccination on prison reception can have a significant impact on the prevalence and incidence of HBV in the IDU population over time.

Original languageEnglish
Pages (from-to)2377-2386
Number of pages10
JournalVaccine
Volume24
Issue number13
DOIs
Publication statusPublished - 20 Mar 2006

Bibliographical note

Funding Information:
Thanks to Matthew Hickman and Emilia Vynnycky for additional helpful comments. This work was supported by Prison Health at the Department of Health and Imperial College London.

Keywords

  • Hepatitis B vaccination
  • Injecting drug users
  • Prison

Fingerprint

Dive into the research topics of 'Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales'. Together they form a unique fingerprint.

Cite this